Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 4 2Phase 2 2Phase 2/3 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1CNS 1Breast 1

Conditions

Kidney Neoplasms 1Carcinoma, Renal Cell 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 280Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Completed × Ranitidine × Clear all
NCT01332630 2018-09-20

TPI 287 in Breast Cancer Metastatic to the Brain

M.D. Anderson Cancer Center

Phase 2 Completed
24 enrolled 8 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00030992 2012-08-20

BMS 247550 to Treat Kidney Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
102 enrolled 10 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡